Linaclotide for irritable bowel syndrome with constipation: A 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety

American Journal of Gastroenterology

Volumn 107, Issue 11, 2012, Pages 1702-1712

  Chey, William D ^a   Lembo, Anthony J ^b   Lavins, Bernard J ^c   Shiff, Steven J ^d   Kurtz, Caroline B ^c   Currie, Mark G ^c   MacDougall, James E ^c   Jia, Xinwei D ^d   Shao, James Z ^c   Fitch, Donald A ^c   Baird, Mollie J ^c   Schneier, Harvey A ^d   Johnston, Jeffrey M ^c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c IRONWOOD PHARMACEUTICALS INC   (United States)

^d FOREST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINACLOTIDE; PLACEBO;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ARTICLE; BLOATING; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLATULENCE; FOOD AND DRUG ADMINISTRATION; GASTROESOPHAGEAL REFLUX; HUMAN; INTESTINE MOTILITY; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; UPPER RESPIRATORY TRACT INFECTION; VIRAL GASTROENTERITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CONSTIPATION; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PEPTIDES; PLACEBOS; TREATMENT OUTCOME;

EID: 84869491248     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2012.254     Document Type: Article

References (23)

1. Longstreth GF, Thompson WG, Chey WD et al. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
2. Hungin AP, Chang L, Locke GR et al. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther 2005; 21: 1365-75. (Pubitemid 40813683)
3. Brandt LJ, Chey WD, Foxx-Orenstein AE et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastro enterol 2009; 104 (Suppl 1): S1-S35.
4. Hungin AP, Whorwell PJ, Tack J et al. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40, 000 subjects. Aliment Pharmacol Ther 2003; 17: 643-50. (Pubitemid 36418887)
5. Drossman DA, Camilleri M, Mayer EA et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 2108-31. (Pubitemid 35408332)
6. ParéP. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study. Clin Ther 2006; 28: 1726-35.
7. Mayer EA. Clinical practice: irritable bowel syndrome. N Engl J Med 2008; 358: 1692-9.
8. Bryant AP, Busby RW, Bartolini WP et al. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci 2010; 8: 19-20.
9. Eutamene H, Bradesi S, Larauche M et al. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil 2010; 22: 312-22.
10. Castro J, Martin C, Hughes PA et al. A novel role of cyclic GMP in colonic sensory neurotransmission in healthy and TNBS-treated mice. Gastroenterology 2011; 140: S-538.
11. Johnston JM, Kurtz CB, Macdougall JE et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology 2010; 139: 1877-86.
12. Andresen V, Camilleri M, Busciglio IA et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-redominant irritable bowel syndrome. Gastroenterology 2007; 133: 761-8. (Pubitemid 47374145)
13. U.S. Department of Health and Human Services. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims 2009.
14. Guidance for industry: irritable bowel syndrome-clinical evaluation of drugs for treatment. Food and Drug Administration 2012 Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/UCM205269.pdf. Accessed 4 June 2012.
15. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997; 32: 920-4. (Pubitemid 27382038)
16. Winawer S, Fletcher R, Rex D et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 2003; 124: 544-60. (Pubitemid 36169269)
17. Spiegel B, Strickland A, Naliboff BD et al. Predictors of patient-assessed illness severity in irritable bowel syndrome. Am J Gastroenterol 2008; 103: 2536-43.
18. Farrar JT, Young JP, LaMoreaux L et al. Clinical importance of changes in chronic pain intensity measured on an 11-oint numerical pain rating scale. Pain 2001; 94: 149-58. (Pubitemid 33016608)
19. Spiegel B, Bolus R, Harris LA et al. Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scale. Aliment Pharmacol Ther 2009; 30: 1159-70.
20. Dworkin RH, Turk DC, Wyrwich KW et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008; 9: 105-21. (Pubitemid 351147828)
21. SalaffiF, Stancati A, Silvestri CA et al. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain 2004; 8: 283-91. (Pubitemid 38859657)
22. Thompson WG, Longstreth GF, Drossman DA et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45 (Suppl 2): II43-7. (Pubitemid 29434812)
23. Snapinn SM, Jiang Q. Responder analyses and the assessment of a clinically relevant treatment effect. Trials 2007; 8: 31.